Alkem Laboratories ' subsidiary Alkem Wellness has successfully completed the sale of its trade generics business through a final payment of ₹32.5 crore, bringing the total transaction value to ₹532.5 crore.

Transaction Overview

The completion of this sale represents a significant milestone in the company's corporate restructuring strategy. The transaction details are summarized below:

Business Divestiture Impact

The sale of the trade generics business marks a strategic shift for Alkem Wellness, allowing the company to focus resources on other core areas. This divestiture is part of the broader pharmaceutical industry trend where companies are streamlining their portfolios to concentrate on specific therapeutic segments.

The completion of the ₹532.5 crore transaction through the final ₹32.5 crore payment indicates that the sale was structured with multiple installments, with this being the concluding payment to finalize the deal.

Corporate Restructuring

This transaction represents one of the significant corporate actions undertaken by the Alkem group, demonstrating the company's strategic approach to portfolio optimization. The successful completion of the sale provides the company with additional financial flexibility while allowing it to exit the trade generics segment.

The finalization of this business sale concludes a major restructuring initiative that will likely influence the company's operational focus and resource allocation in the pharmaceutical sector.

Alkem Laboratories Limited , a prominent player in the Indian pharmaceutical industry, has completed the transfer of its Trade Generics Business to its wholly-owned subsidiary, Alkem Wellness Limited, with a total consideration of ₹532.5 crores.

Business Transfer Completion

On December 30, 2025, the company announced the completion of the business transfer with the final payment of ₹32.5 crores from Alkem Wellness to the parent company. This brings the aggregate sale consideration to ₹532.5 crores under the Business Transfer Agreement.

Timeline of Events

The strategic restructuring process began with the initial intimation to stock exchanges on December 10, 2024. The Business Transfer Agreement was formally executed on September 26, 2025, setting October 1, 2025, as the effective date for the business transfer on a slump sale basis.

Regulatory Compliance

The disclosure was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Manish Narang signed the regulatory filing, ensuring transparency for investors and stakeholders.

Strategic Impact

This restructuring move represents a significant step in streamlining Alkem Laboratories' operations. By transferring the Trade Generics Business to Alkem Wellness as a going concern, the company has created a more focused operational structure that could enhance resource allocation and operational efficiency across its business segments.

The completion of this ₹532.5 crore transaction marks a milestone in the company's strategic reorganization efforts, positioning both entities for optimized performance in their respective operational areas.